B-cell lymphoma is a type of cancers that affects B lymphocytes. Lymphoma is a kind of “blood cancer” affecting the lymph nodes. B-cell lymphomas tend to develop in older adults and in immune compromised individuals. Excluding Hodgkin’s lymphoma, five types of B-cell lymphomas are most common, i.e., Diffuse Large B-Cell Lymphoma (DLBCL), follicular lymphoma, marginal zone B-cell lymphoma, Chronic Lymphocytic Lymphoma (CLL), and Mantle Cell Lymphoma (MCL). The classical therapeutic strategy to B-cell lymphomas is radiation therapy with chemotherapy, called R-CHOP (Rituximab, cyclophosphamide, hydroxydaunomycin, oncovin and prednisone) but the therapeutic limitation is very clear.
One of the most recent therapies for B-cell lymphomas is chimeric antigen receptor (CAR) T cell therapy. Yescarta (Kite Pharma) and Kymriah (Norvatis Pharmaceuticals) are CD19 CAR-T cell therapies targeting a B-lymphocyte antigen, CD19 of B-cell lymphomas. The therapeutic results of CD19 CAR-T cells on B-cell lymphomas are very promising and it was cured many patients suffering from the deadly disease. However, CD19 CAR-T cell therapy has remarkable weaknesses, in that it kills normal B-cells as well as lymphoma B-cells.
Alternatively, TeraImmune developed a distinct technology to target a B cell receptor (BCR) with a specific peptide, called B-cell Antibody Receptor (BAR) technology. With BAR technology, we target cancer cells without affecting normal B-cells. The TI-385 pipeline of TeraImmune is a next generation chimeric receptor technology that improves the chance to attack B-cell lymphoma cells. With the success of TI-385 pipeline, TeraImmune expects the development of a novel cell therapeutics to treat DLBCL and follicular lymphoma, followed by other lymphomas.